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Abstract
Vascular endothelial growth factor-A (VEGF) is produced by most cancer cells as multiple isoforms, which display distinct
biological activities. VEGF plays an undisputed role in tumour growth, vascularisation and metastasis; nevertheless the
functions of individual isoforms in these processes remain poorly understood. We investigated the effects of three main
murine isoforms (VEGF188, 164 and 120) on tumour cell behaviour, using a panel of fibrosarcoma cells we developed that
express them individually under endogenous promoter control. Fibrosarcomas expressing only VEGF188 (fs188) or wild type
controls (fswt) were typically mesenchymal, formed ruffles and displayed strong matrix-binding activity. VEGF164- and
VEGF120-producing cells (fs164 and fs120 respectively) were less typically mesenchymal, lacked ruffles but formed
abundant cell-cell contacts. On 3D collagen, fs188 cells remained mesenchymal while fs164 and fs120 cells adopted
rounded/amoeboid and a mix of rounded and elongated morphologies respectively. Consistent with their mesenchymal
characteristics, fs188 cells migrated significantly faster than fs164 or fs120 cells on 2D surfaces while contractility inhibitors
accelerated fs164 and fs120 cell migration. VEGF164/VEGF120 expression correlated with faster proliferation rates and lower
levels of spontaneous apoptosis than VEGF188 expression. Nevertheless, VEGF188 was associated with constitutively active/
phosphorylated AKT, ERK1/2 and Stat3 proteins. Differences in proliferation rates and apoptosis could be explained by
defective signalling downstream of pAKT to FOXO and GSK3 in fs188 and fswt cells, which also correlated with p27/p21
cyclin-dependent kinase inhibitor over-expression. All cells expressed tyrosine kinase VEGF receptors, but these were not
active/activatable suggesting that inherent differences between the cell lines are governed by endogenous VEGF isoform
expression through complex interactions that are independent of tyrosine kinase receptor activation. VEGF isoforms are
emerging as potential biomarkers for anti-VEGF therapies. Our results reveal novel roles of individual isoforms associated
with cancer growth and metastasis and highlight the importance of understanding their diverse actions.
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Introduction
Vascular endothelial growth factor-A (VEGF) plays a funda-
mental role in tumour growth, vascularisation and metastasis and
exists as multiple isoforms derived by alternative splicing of the
VEGF gene [1]. Mouse and human proteins of 120/121, 164/165
and 188/189 amino acids respectively, represent major VEGF
splice variants with distinct properties and expression patterns.
These isoforms differ in terms of binding affinities to the
extracellular matrix and receptor activation. Tumours display
highly variable levels of relative isoform expression, with VEGF-
164/165 and VEGF120/121 generally being the most predom-
inant and VEGF-188/189 relatively less abundant [2]. VEGF
signals through tyrosine kinase receptors VEGFR1/flt-1,
VEGFR2/flk-1 and VEGF3/flt-4 [3]. VEGF also binds neuropilin
co-receptors (NRP-1 and NRP-2), which lack tyrosine kinase
activity but regulate the function of VEGF receptors as well as
other receptor tyrosine kinases (RTKs) [3]. The different affinities
to matrix, displayed by the various VEGF splice variants generate
gradients in vivo and result in different signalling responses, which
are important for angiogenesis [4,5]. VEGF also has complex
functions in angiogenesis-independent aspects of tumour growth
and tumour cells have been shown to express functional VEGF
receptors [6,7,8] but the role of individual VEGF isoforms in these
processes remains poorly understood.
VEGF and its receptors are now major targets of several cancer
therapies. Anti-VEGF agents such as the humanised neutralising
anti-VEGF antibody bevacizumab as well as several VEGF
receptor kinase inhibitors are being used to treat many types of
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cancer. However, not all patients respond to anti-VEGF therapy
and therefore biomarkers that can predict clinical response are
being actively pursued [9]. Indeed, several recent retrospective
clinical studies have identified the short soluble isoforms of VEGF
(VEGF120 and 110) as promising potential biomarkers for
predicting responsiveness to bevacizumab [10,11,12]. Pancreatic,
breast and gastric cancer patients with higher circulating levels of
short VEGF121 and VEGF110 isoforms were shown to have a
shorter median overall survival but were more likely to benefit
from treatment with bevacizumab. Importantly, the short VEGF
isoforms were identified out of a comprehensive range of potential
biomarker candidates that were examined in these studies [8,9,10].
These studies highlight the importance of understanding of the
complexities associated with the functions of individual VEGF
isoforms in cancer.
Immortalization and transformation of mouse embryonic
fibroblasts results in cell lines with tumorigenic potential. Such
cells derived from genetically modified animals are useful for
studying the role of specific genes in cancer progression [13].
Using this approach we developed VEGF isoform-specific
fibrosarcomas [14] by H-rasV12 transformation of embryonic
fibroblasts derived from transgenic animals expressing single
VEGF isoforms and wild type controls [15,16]. These cells
produced tumours in vivo that displayed distinct vascular patterns,
similar to those seen in corresponding transgenic animals during
development. Furthermore, the tumours displayed differences in
response to treatment with vascular targeting agents highlighting
the importance of VEGF isoform expression in treatment outcome
[14,17]. When grown in vitro, the fibrosarcoma cells exhibited
major differences in growth rates, with VEGF164 and VEGF120
expressing cells (fs164 and fs120 respectively) proliferating
significantly faster than VEGF188 (fs188) and wild type control
cells (fswt) [14] suggesting that VEGF isoform expression also
controls tumour cell growth characteristics. Initial growth rates
were also faster for fs164 and fs120 tumours in vivo, which are
consistent with the highly proliferative phenotype of the cells [14].
Proliferation and survival of cancer cells is maintained by
constitutive activation of multiple complex signalling pathways
that ordinarily maintain tight control in normal cells [18].
Mutated proto-oncogenes such as Ras can cause aberrant
signalling through the Raf/MEK/ERK1/2 and PI3K/AKT
signalling cascades that regulate tumour cell growth and survival.
Multiple signalling mechanisms also converge to co-ordinate
tumour cell invasiveness and migration. In particular, assembly of
the actin cytoskeleton, under the control of the Rho family of
GTPases, is required so that protrusions and contractile forces can
be generated to propagate cell movement [19]. Cancer cells move
either individually or collectively as multicellular clusters and
maintain the capacity to switch from one mode of movement to
another. Individual cell migration is classified as either ‘‘mesen-
chymal’’ or ‘‘amoeboid’’ and each mode has different require-
ments for contractility, attachment to matrix and proteolysis [20].
VEGF is known to contribute to intracrine and autocrine
tumour cell growth, survival, migration and invasion [7,8]. We
hypothesise that individual isoforms of VEGF might influence
various aspects of tumour cell behaviour in a distinct manner.
Using the fibrosarcoma cells we developed, which express single
VEGF isoforms and, in parallel, wild type control fibrosarcoma
cells capable of expressing all isoforms, we investigate here the
consequences of endogenous isoform expression on tumour cell
morphology, proliferation, survival and migration. Using this
system, in which VEGF expression is maintained under the
control of its endogenous physiological promoter, we have
discovered that individual isoforms are associated with distinct
roles in terms of tumour cell behaviour and gained insight into
signalling pathways that are linked with these effects.
Materials and Methods
Ethics statement
Animal experiments were conducted according to United
Kingdom Animals (Scientific Procedures) Act 1986 (UK Home
Office Project Licence PPL40/3110) and with local University of
Sheffield ethical approval.
Reagents
Blebbistatin, UO126, Y27632 and pyridone 6 (P6) were
purchased from Calbiochem. SU11248 (sunitinib) was purchased
from LC laboratories. Antibodies to integrin b1, ILK, pAKT
(ser473), p70S6 (thr389), pGSK-3 (ser21/9), pFOXO-1 (ser256),
p-Stat3 (tyr705), VEGFR2, pVEGFR2 (tyr996), pVEGFR2
(tyr1175) and GAPDH were from Cell Signalling. Anti- actin,
pERK, tERK and b-tubulin antibodies were from Sigma. N-
cadherin, p21 and p27 antibodies were from BD Biosciences and
LIF antibody was from R&D Systems. VEGFR1 (ab32152 and
ab2350) and pVEGFR1 (tyr1333) antibodies were from Abcam.
Recombinant VEGF164, VEGF165 and VEGF120 proteins were
purchased from Peprotech. Recombinant VEGF188 protein was
purchased from Reliatech GmbH.
Cell culture
Fibrosarcoma cell lines (fs188, fs164, fs120 and fswt) were
developed as we described before [14], from fibroblasts derived
from transgenic mouse embryos expressing single VEGF isoforms
VEGF188, VEGF164, VEGF120 and wild type controls respec-
tively [15,16]. Cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM), 10% FCS, 600 mg/ml G418 and 2 mg/
ml puromycin (Invitrogen, UK). The mouse endothelial H5V cell
line was a gift from Dr Annunciata Vecchi [21]. H5V cells were
maintained in DMEM containing 10% FCS. Human umbilical
vein endothelial cells (HUVEC) from pooled donors were
purchased from PromoCell and were maintained in endothelial
cell growth medium (PromoCell).
Preparation of conditioned media
Cells were grown to 50% confluence and then switched to
serum-free DMEM for 48 h. Conditioned media were concen-
trated 30-fold with Microcon concentrators (Merck Millipore) and
normalised to cell numbers before they were analysed by
immunoblotting.
Preparation of collagen, fibronectin and laminin matrices
A thin coating of monomeric collagen was prepared by
incubating culture plates for 2 h with 50 mg/ml rat tail collagen
type I (BD Biosciences) diluted in 0.02 N acetic acid. Bovine
fibronectin (Invitrogen, UK) or laminin-1 (Sigma) were diluted to
5 mg/ml in PBS and used to coat dishes for 2 h. To prepare a thick
layer of fibrillar matrix, ice-cold rat-tail type I collagen was diluted
to 1.5 mg/ml with 10XDMEM and sterile dH2O. The solution
was neutralised with NaOH and allowed to polymerise at 37uC
before plating the cells on top.
Adhesion and cell spreading assays
Adhesion assays were performed in 96-well plates pre-coated
with fibronectin, laminin or collagen and blocked in 0.1% BSA.
Cells (36104) suspended in serum-free DMEM/0.1% BSA were
plated in each well, and plates were immediately incubated at
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37uC for 45 min. Adherent cells were fixed, stained with 0.5%
crystal violet and lysed in 2% SDS. Absorbance was measured at
570 nm using a BMG FLUORStar Galaxy microplate reader. For
monitoring spreading, cells were re-suspended in DMEM/0.1%
BSA and plated in Lab-Tek 4-well permanox chamber slides
(Nalge-Nunc) (16105 per well) pre-coated with collagen, laminin
or fibronectin. The slides were incubated at 37uC for 30 min to
3 h and then cells were stained as described below.
Analysis of cell morphology and cytoskeletal F-actin
staining
Live cells were stained with 2.5 mg/ml CellMask plasma
membrane stain (Invitrogen, UK) for 5 min, fixed in 3.7%
formalin and mounted in Vectashield (Vector Laboratories).
Analysis of F-actin was performed as we described previously
[22]. Fluorescence images were taken with a Leica DMI4000B
fluorescence microscope and using LASAF control and analysis
software.
Growth curves and doubling times
Cells were plated in 6-well plates (46104 per well). Viable cells
were counted daily for 4–6 days using a Vi-Cell automated cell
viability analyzer (Beckman Coulter). Media were replenished
every other day. Doubling times were established by plotting a
graph of log 2 (N/N0) (N0= initial cell numbers and N= end-
point average cell numbers) against time followed by calculating
the inverse slope of the linear part of the curve.
Colony formation in soft agar
Cells were suspended in medium containing 0.33% agarose and
plated over a 0.5% agarose underlay in 6-well plates (26103 cells/
well). Three weeks later, colonies were stained with 0.005% crystal
violet and counted in 10 random fields using a 46 objective.
Analysis of apoptosis
Apoptotic cell death was measured by flow cytometry using the
ApoAlert MitoSensor Kit (Clontec) which detects alterations in
mitochondrial membrane potential. Apoptosis was also quantified
using the Cell Death Detection ELISAPLUS kit (Roche Diagno-
sitics), which measures cytoplasmic DNA-histone nucleosome
complexes. For both assays cells were plated at a density of 104
cells/cm2 and apoptosis was determined 48 h later. Apoptosis in
tumour sections was detected by TUNEL assay using the ApoTag
Plus Peroxidase In Situ Apoptosis Detection kit (Chemicon
International). Apoptotic cells were scored using a 406 objective
in 6–9 random fields of view per tumour section avoiding areas of
necrosis. Data are expressed as mean number of TUNEL positive
apoptotic cells per mm2.
Migration assay
Migration was measured using Ibidi cell culture inserts. Cells
(3.56104) in 70 ml medium were plated into each insert
compartment and grown for 48 h. The inserts were removed to
create a gap/wound of 500 mm into which the cells migrated. The
cells were imaged immediately and at intervals for up to 24 h with
a Nikon Eclipse phase contrast microscope equipped with a Digital
Slight DS camera and NIS-Elements software. Wound closure was
quantified with an automatic image analysis algorithm [23] using
the CAIMAN image analysis website (http://www.caiman.org.
uk/).
Subcutaneous tumour generation
Fibrosarcoma cells (16106 in 50 ml serum-free DMEM) were
injected subcutaneously into the rear dorsum of female 8–12 week-
old SCID mice. Tumours were excised when they reached a mean
diameter of 6–8 mm (usually 10–14 days post-implantation) and
were either embedded in paraffin and sectioned for analysis of
apoptosis, or were frozen for protein extraction.
Immunoblotting
Proteins from cells and tumours were extracted with NP40 Lysis
Buffer (Biosource, Invitrogen) supplemented with phosphatase and
protease inhibitors. Equal amounts of protein (10–50 mg/lane)
were separated on NuPAGE Novex gels (Invitrogen), transferred
to nitrocellulose or PVDF membranes and immunoreactive bands
were visualized using ECL reagents (GE Healthcare).
Statistical analysis
Data were analysed by using a one-way analysis of variance
(ANOVA), followed by the Tukey-Kramer post-test test for
multiple comparisons using GraphPad Prism software for Mac
OS X. A 2-way ANOVA followed by a Bonferroni post-test was
used for analyzing multiple groups with more than one variable
(treatment and cell type). In all cases, differences between groups
were described as significant if the probability was ,0.05.
Results
Fibrosarcoma cells expressing individual VEGF isoforms
differ in morphology and adhesion properties
Fs188 as well as fswt cells, which express all isoforms including
VEGF188, display typical mesenchymal features (Figure 1a,b).
The cells are elongated and spindle-shaped, have extended
processes and ruffles and do not form extensive cell-cell
associations. In contrast, fs164 do not display a typical mesenchy-
mal morphology. These cells grow in very close association with
each other and closely align longitudinally forming long multicel-
lular chains. Fs120 cells also grow in close association with each
other, although less so than fs164 cells, and also have fewer
extended processes than fs188 and fswt cells. On fibrillar collagen,
fswt and fs188 cells retained their mesenchymal features while
fs164 cells were rounded/amoeboid and fs120 cells displayed a
mix of rounded and elongated features (Figure 2a). All fibrosar-
coma cells stained diffusely for F-actin (Figure 2b), a characteristic
feature of Ras transformation, which elevates ERK MAPK
signalling and uncouples Rho-GTP signalling from stress fibre
formation [24,25]. Inhibition of ERK activator MEK with U0126
reversed the effects of transformation on F-actin, and re-
established stress fibers in all the cell lines (Figure 2c). In addition,
fs120 cells assumed a more mesenchymal morphology and
displayed more extended processes. Fs164 cells expressed stress
fibres upon MEK inhibition although their distinct close cell-cell
alignment was still evident, suggesting that this feature was not
MEK-dependent.
Fswt and fs188 cells adhered better to uncoated plastic and
collagen than fs164 and fs120 cells (Figure 3a). On the other hand,
fs164 and fs120 cells adhered better to laminin than fswt and fs188
cells. All four cell lines adhered to and also spread avidly and
rapidly on fibronectin (Figure 3a, b). All cells also spread on
laminin but fs164 and fs120 cells failed to spread on collagen, even
after 3 h and in the presence of serum (Figure 3b). All the
fibrosarcoma cells expressed integrin b1 and integrin-linked kinase
(ILK) (Figure 3c), an adaptor protein that is recruited to integrin
b1 cytoplasmic domains and associates with actin at focal
adhesions [26]. ILK expression levels were higher in fswt and
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fs188 compared to fs164 and fs120 cells. All fibrosarcomas also
expressed N-cadherin (Figure 3c), a classic mesenchymal marker
[27]. Levels of N-cadherin were up-regulated in fs164 and fs120
cells, which also formed more cell-cell contacts (also see Figure 1).
Fibrosarcoma cells expressing individual VEGF isoforms
proliferate at different rates and display differences in
levels of spontaneous apoptosis
We previously showed that fs164 and fs120 cells proliferated on
plastic at significantly faster rates than fswt and fs188 cells [14].
Integrin-matrix interactions play an important role in controlling
cell proliferation. However, neither collagen nor fibronectin had
any significant effect on growth, and the differences in prolifer-
Figure 1. Morphology of fibrosarcoma cells expressing single VEGF isoforms. a): Phase contrast images of cells grown on uncoated tissue
culture plastic. b): Cells grown on plastic and stained live with CellMask Orange. Scale bars, 50 mm.
doi:10.1371/journal.pone.0104015.g001
Figure 2. Morphology of fibrosarcoma cells on thick fibrillar collagen and after inhibition of MEK. a): Cells on a thick layer of type I
collagen; b): cells grown on uncoated plastic and stained for F-actin. c): Cells treated with MEK inhibitor U0126 (10 mM) for 18 h and stained for F-
actin. Scale bars, 50 mm.
doi:10.1371/journal.pone.0104015.g002
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ation between the cell lines persisted (Table I). Growth in soft
agar, an indication of tumourigenic capacity, was also significantly
different between the cell lines; fs164 and fs120 cells producing
significantly more colonies than fswt and fs188 cells (Table II and
also see Figure S1). Apoptosis was significantly more pronounced
in fswt and fs188 cells than in fs164 and fs120 cells (Figure 4a,b).
Similarly, in vivo, there were significantly more apoptotic cells
within viable regions of fs188 solid tumours compared to tumours
generated by fs164 and fs120 cells (Figure 4c,d).
Fibrosarcoma cells expressing individual VEGF isoforms
migrate at different rates on 2D surfaces
Fswt and fs188 cells migrated significantly faster than fs164 and
fs120 cells on 2D uncoated plastic (Figure 5). The faster migration
of VEGF188-expressing cells was consistent with their mesenchy-
mal morphology and presence of ruffles (see Figure 2b), an
indication of intense migratory activity [28]. Migration rates on
thin collagen were similar to migration rates on uncoated plastic
(data not shown).
Migration of fs164 and fs120 cells is actinomyosin
contractility-dependent
Cell morphology and migration are dependent on the
cytoskeleton and actinomyosin contractility, to provide traction
force in mesenchymal movement, and cortical contraction for
rounded amoeboid movement [19,29]. Cells were treated with
pharmacological inhibitors of contractility, including ROCK
inhibitor Y27632, myosin II ATPase inhibitor blebbistatin and
JAK inhibitor P6. The latter was shown to inhibit actinomyosin
contractility in melanoma cells [30]. Figure 6a shows that all three
inhibitors caused fs164 and fs120 cells to switch to a mesenchymal
morphology (compare Figure 6a with Figure 1) and accelerated
their migration but not that of fswt and fs188 cells (Figure 6b). P6
inhibited MLC phosphorylation in all the fibrosarcoma cells
(Figure 6c) as previously shown for melanoma cells [30] but
interestingly also induced a marked up-regulation of integrin b1
(Figure 6c).
Figure 3. Fibrosarcoma cell adhesion and spreading. a): Cell adhesion to uncoated plastic or plastic coated with collagen I, fibronectin or
laminin-1 at 45 min. * and ** represent significant differences, (*p,0.05 and **p,0.01) by two way ANOVA followed by Bonferroni post-test. b): Cell
spreading on fibronectin and laminin at 30 min, on a thin layer of collagen at 3 h or on collagen for 3 h in the presence of 2% FCS (collagen+S). Cells
were stained live with with CellMask orange. Scale bars, 50 mm. c): Immunoblot analysis for b1 integrin (b-Itg) ILK and N-cadherin. Blots were
normalised to actin. Results are representative of at least 3 independent experiments.
doi:10.1371/journal.pone.0104015.g003
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Fibrosarcoma cells expressing individual VEGF isoforms
exhibit differences in growth and survival-associated
signalling
We next investigated signalling mechanisms that could poten-
tially account for the observed differences in cell growth, survival
and migration. Signalling via AKT promotes growth through
activation of the mTOR1 complex and downstream targets such
as p70S6 kinase involved in cell growth and G1 cell cycle
progression [18]. AKT and p70S6 were more highly phosphor-
ylated in fswt and fs188 cells, compared to fs164 and fs120 cells
(Figure 7a) and this was independent of cell density (data no
shown). Overnight exposure to PI3K inhibitor LY29004 reduced
constitutive phospho-AKT and p70S6 levels (Figure 7a). AKT
also signals through FOXO and glycogen synthase kinase-3 (GSK-
3) to regulate survival, metabolism and growth [31]. GSK-3 is
active when unstimulated and becomes switched off upon
phosphorylation by AKT. FOXO1 is also phosphorylated and
inactivated by AKT and this action blocks its transcriptional
activity on genes that promote apoptosis and regulate metabolism.
Paradoxically, levels of pGSK-3 and pFOXO1 did not parallel
AKT and p70S6 phosphorylation (Figure 7b). Higher levels of
phosphorylated FOXO1 were detected in fs164 and fs120 cells in
which basal pAKT was low, suggesting that AKT signalling was
uncoupled from this downstream branch of the pathway.
Similarly, pGSK-3 was not upregulated as might be expected in
VEGF188-expressing cells. Both FOXO1 and GSK-3 mediate cell
cycle arrest by regulating expression and stability of cyclin-
dependent kinase inhibitors (CDKIs) [32,33]. In fs188 cells, CDKI
p27 was significantly upregulated, while in fswt cells expression of
CDKI p21 was higher than in the other lines (Figure 7b).
Increased phosphorylation of p44 and p42 ERKs was also seen
in fswt//fs188 versus fs164/fs120 cells (Figure 7c). Constitutive
activation of JAK/Stat3 is a feature of cancer cells where its major
function is to promote proliferation and survival [34]. Phospho-
Stat3 levels were consistently higher in fswt and fs188 cells,
compared to fs164 and fs120 cells; pan-JAK inhibitor P6 blocked
Stat3 phosphorylation in all cell lines (Figure 7d). A similar pattern
of pStat3 was evident in sub-confluent as in post-confluent cultures
(data not shown), which demonstrated that unlike other systems its
expression was not density-dependent [35]. Stat3 phosphorylation
was also up-regulated in fs188 tumours in vivo (Figure 7e).
Although Stat3 signalling is primarily associated with proliferation
and survival, previous studies have shown that sustained activation
of Ras/Raf/ERK led to the production of leukemia inhibitory
factor (LIF), which then signaled through JAK/Stat3 in an
autocrine or paracrine manner to mediate cell cycle arrest [36].
Figure 7f shows that fs164 and fs120 cultures produced signifi-
cantly more secreted LIF than fswt and fs188 cells. It is therefore
unlikely that signalling through LIF was responsible for the
differences in levels of active JAK/Stat3 that were seen between
the cell lines.
Fibrosarcoma cells express tyrosine kinase VEGF
receptors, which cannot be activated by VEGF
We next explored the possibility that the observed differences in
growth and survival-associated signalling were due to VEGF
isoform-dependent autocrine actions. All fibrosarcoma cells
expressed similar levels of VEGF receptor 2 (VEGFR2/flk-1)
(Figure 8a) which could potentially mediate autocrine signalling.
However, VEGFR2 was not constitutively phosphorylated/acti-
vated in any of the cells (not shown), and furthermore, exogenously
added recombinant murine VEGF164 failed to activate its
phosphorylation either at tyrosine 996 (Figure 8a) or at tyrosine
1175 (Figure 8b). Downstream ERK1/2, AKT and Stat3 were
also not further activated/phosphorylated beyond basal levels by
recombinant VEGF, results that were consistent with the failure of
VEGF to activate its receptor(s) (Figure 8c). In parallel, VEGF
induced robust VEGFR2 and ERK1/2 phosphorylation in
HUVEC and H5V mouse endothelial cells (Figure 8a,b). In
addition to VEGF164, other recombinant VEGF isoforms
(VEGF120, VEGF188 and VEGF165) were tested over a range
of concentrations (1, 10 and 100 ng/ml) but in all cases induction
of VEGFR2 and/or ERK1/2 phosphorylation was not detected
(data not shown). The VEGF receptor tyrosine kinase inhibitor
SU11248 [37] blocked both basal and VEGF-induced VEGFR2
and pERK phosphorylation in H5V cells (Figure 8a) and HUVEC
(data not shown) but interestingly had no effect on basal levels of
pERK1/2 in the fibrosarcomas (Figure 8d). These results suggest
Table 1. Population doubling times (hours) of fibrosarcoma cells grown on 2D surfaces.
fswt fs188 fs164 fs120
Plastic 18.3660.29 (n = 6) 17.8960.336 (n = 6) ***13.8960.57 (n = 6) ***13.6760.26 (n = 6)
Collagen 16.9860.92 (n = 6) 17.1760.24 (n = 3) **13.1560.09 (n = 3) *14.4960.46 (n = 3)
Fibronectin 19.4161.175 (n = 6) 18.8761.55 (n = 3) ***13.5560.24 (n = 3) ***14.5960.69 (n = 3)
Population doubling times (hours) of cells grown on plastic, collagen or fibronectin are means of 3–6 independent experiments 6 SEM.
*p,0.05,
**p,0.01,
***p,0.001 values represent differences between fswt/fs188 cells versus fs164/fs120 cells (two way ANOVA followed by Bonferroni post-test).
doi:10.1371/journal.pone.0104015.t001
Table 2. Colonies formed by fibrosarcoma cells grown in soft agar.
fswt fs188 fs164 fs120
Soft Agar 23.462.85 (n = 3) 24.9864.4 (n = 3) *33.863.7 (n = 3) *35.864.2 (n = 3)
Number of colonies in agar are means of three independent experiments 6 SEM.
*p,0.05 represents significantly more colonies formed by fs164 or fs120cells compared to fswt or fs188 cells (ANOVA followed by Tukey-Kramer post-test).
doi:10.1371/journal.pone.0104015.t002
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Figure 5. Migration of fibrosarcoma cells expressing single VEGF isoforms. a): Wound closure was measured at intervals up to 24 h. Each
point represents data obtained from 2–5 independent experiments 6 SEM; b): representative culture images of the four fibrosarcoma cell lines
showing wound closure at 18 h.
doi:10.1371/journal.pone.0104015.g005
Figure 4. Spontaneous apoptosis in fibrosarcoma cells and solid tumours. a): Nucleosome generation in cells measured by ELISA at 48 h.
OD values are averages of 5 independent experiments 6 SEM. b): Changes in cell mitochondrial potential at 48 h. Values are averages6 SEM, from 4
independent experiments. *p,0.05, **p,0.01 represent significance using repeated measures ANOVA followed by Tukey-Kramer post-test. c):
Apoptosis in tumour sections determined by TUNEL assay. Arrows indicate typical apoptotic cell nuclei. Bars, 50 mm. d): Mean number of TUNEL
positive apoptotic cells 6 SEM per mm2 tumour section (viable regions only); n = 5–10 tumours per group. *p,0.05, **p,0.01 and ****p,0.0001
represent significance using repeated measures ANOVA followed by Tukey-Kramer post-test.
doi:10.1371/journal.pone.0104015.g004
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that although the fibrosarcoma cells express VEGFR2, this
nevertheless remains inactive/inactivatable. Furthermore, these
data strongly indicate that the markedly higher levels of
constitutively active pERK1/2, which were evident in fswt/fs188
compared to fs164/fs120 cells were unlikely to have arisen
through VEGF-dependent autocrine activity through tyrosine
kinase VEGF receptors. However, SU11248 caused a significant
reduction in constitutive levels of AKT and Stat3 phosphorylation
of in all the fibrosarcoma cells (Figure 8d); after overnight
incubation with SU11248, the phosphorylation levels of both
AKT and Stat3 returned back to their original basal levels (data
not shown).
The fibrosarcoma cells also expressed full length VEGFR1/flt1
as well as a truncated variant most likely consisting of the
intracellular domain of the receptor (see supplementary data,
Figure S2) previously described in endothelial and breast cancer
cells [38]. The truncated variant was constitutively phosphorylated
at tyr1333 in the fibrosarcomas cells but this phosphorylation
could not be downregulated by SU11248. Phosphorylated
VEGFR1 was also evident in H5V cells; in these cells SU11248
caused a small reduction in VEGFR1 phosphorylation (see Figure
S2).
Discussion
In this study, we demonstrate that endogenous single VEGF
isoform expression is linked to distinct growth, survival and
migratory characteristics in Ras transformed fibrosarcoma cells.
Our model system allowed us to investigate three individual
isoforms of murine VEGF (VEGF188, VEGF164 and VEGF120),
when expressed under the control of the gene’s physiological
promoter, and hence has a distinct advantage compared to over-
expression systems that may alter normal endogenous signalling
interactions. We show that VEGF188 expression is linked to a
slower rate of tumour cell proliferation and decreased survival.
Furthermore, VEGF188 expression was associated with strong
cell-matrix matrix interactions and a mesenchymal morphology
and mode of cell motility in vitro. In contrast, VEGF164 and
VEGF120 endogenous expression was associated with more rapid
cell proliferation, increased survival and a rounded amoeboid
morphology and mode of motility in vitro (summarised in
Figure 9). Differences between the various cell phenotypes are
Figure 6. Analysis of morphology and migration of fibrosarcoma cells exposed to contractility inhibitors. a): Cells were treated with P6
(5 mM), blebbistatin (5 mM) or Y27632 (10 mM) for 18 h. Representative images of P6 treated cells by phase contrast microscopy; blebbistatin-treated
cells stained for F-actin; Y27632 treated cells stained with CellMask Orange. Scale bars, 50 mm. b): Migration was quantified by measuring wound
closure. Images were collected at 12 h for the fswt and fs188 cells, at 18 h for the fs120 cells and at 24 h for the fs164 cells to correlate with 40–60%
wound closure in untreated conditions. Contractility inhibitors were added at the same concentrations used in (a) 18 h before the start of the assay
and replaced in fresh media at assay start. Each point represents data obtained from 3 independent experiments 6 SEM, each conducted with 2–4
replicates. *p,0.05, ***p,0.001 values represent significance over untreated cultures (ANOVA followed by Tukey-Kramer post-test). c): Cells were
incubated overnight with P6 (5 mM). Equal amounts of proteins (30 mg) were analysed for integrin b1 (b-Itg) and pMLC. A representative immunoblot
is shown.
doi:10.1371/journal.pone.0104015.g006
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very unlikely to have arisen by clonal selection during the
generation of the cell lines, as several individual clones isolated
after transformation maintained identical properties to their
corresponding parental lines (data not shown).
The cells we developed are of mesenchymal origin and
accordingly they all constitutively expressed classic mesenchymal
markers such as N-cadherin (Figure 3c), alpha smooth muscle
actin and vimentin (unpublished data). However, despite not
displaying typical mesenchymal features, in terms of their
morphology and migratory characteristics, the fs164 and fs120
cells express higher levels of N-cadherin compared to the more
typically mesenchymal fswt and fs188 cells. We postulate that the
higher levels of N-cadherin protein facilitate and sustain the
distinct cell-cell contacts that fs164 and fs120 cells form in 2D
culture. Indeed, previously it was shown that upregulated N-
cadherin expression mediated cell-cell adhesion by localising to
cell-cell contacts in invasive epithelial MDCK cells after under-
going epithelial-to-mesenchymal transition (EMT) [39].
Differences in adhesion to various matrix proteins are also
suggestive of differences in integrin expression and/or status of
activation. These differences are likely to involve both alpha and
beta integrin subunits. While all fibrosarcomas expressed integrin
b1, fs188 cells expressed higher levels of ILK. ILK stabilises b1
adhesions, is associated with integrin engagement/activation and
was found to be over-expressed in mesenchymal cancer cells
[40,41]. Therefore, upregulated ILK expression could potentially
contribute to a more adhesive mesenchymal fs188 phenotype.
Amoeboid morphology, which is less dependent on integrin-
matrix interactions, is more readily seen in culture when cells are
grown on fibrillar collagen matrices. Indeed, fs164 and to a large
extent fs120 cells were rounded on collagen (Figure 2a). Interest-
ingly, fs164 and fs120 cells have rounded cell morphologies when
grown as subcutaneous tumours in vivo and fs188 tumours retain
an elongated mesenchymal cellular morphology (see Figure 4c).
The extent of anchorage independent growth in agar was
consistent with growth on solid surfaces. Growth in agar reflects
tumorigenic potential and results in vitro correlate with our
previous findings in vivo, where expression of VEGF164 and
VEGF120 was associated with a more rapid initiation of tumour
growth [14].
Although VEGF is a pro-survival factor, there are suggestions
that VEGF188 may elicit pro-apoptotic signals as shown in
Figure 4. Chondrocytes from homozygous VEGF188/188 mice
apoptosed at high rates during development, and could be rescued
by exogenous VEGF164 [42]. In addition, over-expression of
VEGF189 in breast cancer cells induced apoptosis via NRP-1
[43]. Interestingly, the fswt and fs188 cells markedly over-express
NRP1 compared to the other two cell lines (see Figure S2d). It is
therefore possible that NRP-1 may regulate pro-apoptotic
processes associated with VEGF188 expression in the fibrosarco-
mas. Our results are therefore in agreement with the above studies
and suggest that increased pro-apoptotic signalling is an intrinsic
property of VEGF188 expression. It was, however, intriguing that
the pro-survival and pro-proliferative signalling proteins AKT,
ERK1/2 and Stat3, were more highly activated in VEGF188-
expressing cells. A potential explanation for this discrepancy came
from the analysis of downstream PI3K/AKT effectors. While
AKT target p70S6 was phosphorylated, unexpectedly, FOXO1,
Figure 7. Signalling pathway analysis in fibrosarcomas expressing single VEGF isoforms. a–d): Where indicated cells were incubated
overnight with JAK inhibitor P6 (5 mM), or PI3K inhibitor LY20990 (10 mM). Equal amounts of proteins (10–30 mg) were analysed for a): phospho-AKT
(p-AKT) and p70S6; b): pGSK3, pFOXO1, p27 and p21; c): phospho-ERKs1/2 (p-ERK) and total ERK (t-ERK); d): phospho-Stat3 (p-Stat3). e): Proteins
extracted from solid tumours (50 mg/lane) and analysed for pStat3. All blots were normalized with actin or GAPDH and are representative of at least
three independent experiments. f): Concentrated conditioned media normalised against cell numbers, analysed for LIF expression.
doi:10.1371/journal.pone.0104015.g007
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another key target of AKT and regulator of cell cycle and pro-
survival signalling [44], was more highly phosphorylated in fs164
and fs120 cells (Figure 7b). Inactive/phosphorylated FOXO1
correlated with lower levels of p21 and p27 in fs164 and fs120
cells. In contrast, in fs188 cells, p27 was markedly upregulated and
in wild type cells, p21 was more highly expressed, thus correlating
with their slower proliferation rates. The mechanism(s) through
which active AKT signalling couples to p70S6 but not FOXO and
GSK-3 in fs188 remains unclear. PP2A phosphatase regulates the
activity of FOXO1 and GSK-3 [45,46]. It is possible that high
phosphatase activity dephosphorylates FOXO and GSK3 in fs188
cells. Several studies have suggested that the pro-survival function
of AKT can be overridden [47]. Chronic AKT activation can
contribute to apoptosis induction, while many stress-inducing
agents and chemotherapeutic drugs activate AKT. Indeed, pro-
apoptotic agents often activate survival signals, including Stat3 and
ERKs in addition to AKT, as part of a protective response [48].
The fact that Stat3 was highly active in both fs188 cells and solid
tumours in vivo suggest that high levels of Stat3 activity represent
an intrinsic property consequent to VEGF188 expression.
High levels of constitutively phosphorylated AKT and presence
of lamellipodia suggests a link between the PI3K/AKT pathway
and the mesenchymal mode of migration of fswt and fs188 cells.
Our results are in agreement with studies showing that mesen-
chymal cell lines exhibit high levels of AKT phosphorylation
[41,49]. PI3K/AKT signalling is also a critical component of the
epithelial-mesenchymal transition [50,51]. Ras-mediated activa-
tion of ERKs promotes activation of Rac and lamellipodia
formation to drive tumour cell motility [52]. Our results are
therefore in line with these studies and suggest that the features of
cells expressing VEGF-188 are linked with activated Ras/PI3K
and Ras/ERK.
Differential requirement for integrin engagement and matrix
adhesion as well as actinomyosin contractility are major features
that distinguish amoeboid from mesenchymal migration
[20,53,54]. In mesenchymal cells, Rho/ROCK driven contractil-
ity supports the formation of focal adhesions and contractile stress
fibers that can generate traction force for forward movement,
while Rac and Cd42 are required for the extension of protrusions
at the cell’s leading front [28,55]. Mesenchymal movement is also
dependent on integrin-matrix interactions. On the other hand, in
rounded amoeboid cells integrin-matrix adhesive interactions are
weak, while cortical myosin II generated contraction is essential for
migration in 3D matrices [53]. Several studies have shown that
loss of contractility switches cells over to a mesenchymal mode of
movement [30,54,55]. Inhibitors of Rho/ROCK or contractility
impaired amoeboid movement but had minimal effects on
migration in mesenchymal tumour cells thus illustrating that
Rho/ROCK signalling/contractility are essential in amoeboid but
dispensable in mesenchymal motility [30,54,55]. When exposed to
contractility inhibitors, the fs164 and fs120 cells acquired
mesenchymal characteristics (they spread more and formed more
protrusions) and were able to migrate faster on 2D surfaces. Our
results are in agreement with the studies described above in that
inhibitors of contractility had no significant effect on fswt or fs188
cells but altered the morphology and motility of fs164 and fs120
cells. In our study, all the fibrosarcomas expressed similar levels of
phosphorylated MLC, a read-out of actinomyosin contractility
Figure 8. Analysis of VEGFR2 expression/activation in fibrosarcoma cells. a,b,c): Fibrosarcoma cells, HUVEC or H5V endothelial cells were
stimulated with 100 ng/ml recombinant VEGF164 for 10 min. Equal amounts of proteins (10–30 mg) were analysed for a): Phospho-VEGFR2 (tyr996),
total VEGFR2 and pERK1/2. SU11248 (10 mM) was added 5 min prior to VEGF; b): phospho-VEGFR2 (tyr1175) and total VEGFR2610 mM SU11248; c): p-
ERK1/2, pAKT and pStat3. d): Cells were incubated with SU11248 (10 mM) for 1 h before proteins were extracted and analysed for pERK1/2, pAKT and
p-Stat3 (p-Stat3). All blots were normalized with an antibody to b-tubulin and are representative of at least three independent experiments.
doi:10.1371/journal.pone.0104015.g008
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(Figure 6c), suggesting that contractility alone is not sufficient to
dictate morphology and migration. Inhibition of Jak/Stat3
signalling abrogated the phosphorylation of MLC as described
previously for melanoma cells [30] thus establishing this pathway
as a major driver of contractility also in fibrosarcomas. However,
while in melanoma cells, pStat3 correlated with amoeboid mode of
movement, in our system pStat3 expression correlated with a
mesenchymal morphology that was independent of contractility
for migration. Others have shown that mesenchymal hepatocel-
lular cancer cells expressed higher levels of pStat3 compared to
their epithelial counterparts [41]. Interestingly, inhibition of JAK
signalling resulted in a marked upregulation of integrin b1
expression, which correlated with a switch to a more mesenchymal
morphology, particularly in fs164 and fs120 cells.
We hypothesised that the observed differences in the signalling
characteristics of the fibrosarcoma cells could have arisen through
isoform-dependent autocrine activity, mediated by tyrosine kinase
VEGF receptors. However, although the fibrosarcoma cells
expressed RTK VEGF receptors, these could not be activated/
phosphorylated by recombinant VEGF isoforms. Exogenously
added VEGF also failed to activate downstream signalling to
pERK1/2, pAKT and pStat3 in the fibrosarcoma cells, in marked
contrast to its robust activation of VEGF signalling in endothelial
cells. Furthermore, adding back different recombinant VEGF
isoforms had no effect on fibrosarcoma cell proliferation (supple-
mentary Figure S3) and had no influence on cell morphology (data
not shown). Sunitinib (SU11248) a potent RTK inhibitor with
VEGFR selectivity [37] had no effect on basal pERK1/2 levels
further confirming that the intrinsic pERK1/2 levels were
VEGFR-independent. Sunitinib did inhibit pAKT and pStat3
but this is most likely due to inhibition of other RTK targets of
sunitinib, such as PDGFRb. Previously it was shown that VEGF
produced by renal carcinoma cells promoted tumour cell growth
through activating NRP-1 receptors and downstream Ras [7].
While our results cannot exclude an involvement of NRP-1 in
autocrine signalling, the fact that various recombinant VEGF
isoforms failed to activate pERK, pAKT or pStat3 signalling or
alter the proliferation of the fibrosarcoma cells does not support
such an involvement.
Taken together our data suggest that the inherent differences in
signalling, proliferation, survival and migration between our
different cell lines are a result of complex interactions governed
Figure 9. Schematic of proposed signalling interactions and morphological and motility characteristics of fibrosarcomas
expressing single VEGF isoforms. Differences in PI3K/AKT, Ras/Raf/MEK/ERK and JAK/Stat3 signalling between fswt/fs188 and fs164/fs120 cells
are shown. Upregulation/downregulation of activities or levels of expression of individual proteins are indicated by up or down arrows. VEGF188
expression is associated with reduced proliferation rates, increased apoptosis and typical integrin-dependent mesenchymal morphology and
migration mode. VEGF164/VEGF120 expression is associated with faster proliferation rates, increased survival and rounded/amoeboid integrin-
independent morphology and mode of motility. Migration of fs164/fs120 but not fswt/fs188 cells is contractility-dependent.
doi:10.1371/journal.pone.0104015.g009
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by endogenous VEGF isoform expression, that are independent of
simple ligand-receptor activation. VEGF 189 has been shown to
localise to the nucleus [56,57], which could be significant here.
Although the function of VEGF in the nucleus has not been
established, nuclear localised VEGFD was found associated with c-
myc and RNA polymerase II and regulated c-myc-dependent gene
transcription in fibroblasts in a VEGF receptor-independent
manner [58]. It is therefore possible that VEGFA isoforms also
have intracrine activity that is not dependent on classic receptor
activation.
In summary, we present, for the first time, evidence that
VEGF188 expressed by tumour cells is associated with mesen-
chymal motility, slower proliferation, and increased apoptosis,
while VEGF164 and VEGF120 are associated with a more
rounded/amoeboid morphology and increased proliferation and
survival. Both amoeboid and mesenchymal modes of movement
are important in metastasis and different targeting approaches
may be needed to attack different invasive strategies. In this
respect, it is of interest that VEGF189 isoform over-expression was
shown to correlate with metastasis and poor prognosis in colon
and lung cancer [59,60]. Deciphering the various processes by
which individual VEGF isoforms contribute to tumour growth is
important for the design of cancer therapies. Until now, such
therapies focused on targeting VEGF signalling with an aim to
impair angiogenesis. The demonstration that other non-angiogen-
esis dependent aspects of tumour growth are reliant on VEGF
isoform expression adds to the complexity of VEGF signalling
within the tumour microenvironment and necessitates a better
understanding of the molecular mechanisms involved.
Supporting Information
Figure S1 Growth of fibrosarcoma cells in soft agar.
Colonies formed by fibrosarcoma cells grown in soft agar and
imaged using a 106 objective.
(TIF)
Figure S2 VEGFR1 and NRP-1 expression by fibrosar-
coma cells. a) Schematic diagram showing VEGFR1 domains
recognised by two different commercial VEGFR1 antibodies
(Abcam). Antibody ab32152 was raised against a synthetic peptide
corresponding to residues in the N-terminal extracellular domain
of VEGFR1 and antibody ab2350 was raised against a synthetic
peptide to C-terminal residues, within the tyrosine kinase domain
of the receptor; b) ab32152 recognized the full length receptor
(180 kDa) in fibrosarcoma cells while antibody ab2350 recognised
the full-length receptor as well as a truncated variant (120 kDa)
most likely corresponding to the receptor intracellular domain.
The truncated variant was also present in endothelial cells. c) The
truncated variant was constitutively phosphorylated at tyr1333 in
both fibrosarcoma and H5V cells but its phosphorylation could
not be blocked by SU11284. d) NRP-1 expression in the
fibrosarcomas.
(TIF)
Figure S3 Fibrosarcoma cell proliferation in the pres-
ence of recombinant VEGF isoforms. Cells were plated in 6-
well plates at a density of 26104 cells per well for and treated with
the indicated amounts of recombinant VEGF isoforms. a) fs164
cells were treated with rVEGF164 or rVEGF188; b) fs120 cells
were treated with rVEGF120 or rVEGF188; a,b) Cells were
counted after 5 days in culture. Results (cell counts 6SD) are from
one of two repeat experiments.
(TIF)
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